| Chapter title |
Development of Recombinant Canarypox Viruses Expressing Immunogens
|
|---|---|
| Chapter number | 2 |
| Book title |
Recombinant Virus Vaccines
|
| Published in |
Methods in molecular biology, April 2017
|
| DOI | 10.1007/978-1-4939-6869-5_2 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-6867-1, 978-1-4939-6869-5
|
| Authors |
Garanzini, Débora, Del Médico-Zajac, María Paula, Calamante, Gabriela, Débora Garanzini, María Paula Del Médico-Zajac, Gabriela Calamante |
| Editors |
Maureen C. Ferran, Gary R. Skuse |
| Abstract |
Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 1 | 33% |
| Student > Postgraduate | 1 | 33% |
| Unknown | 1 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Veterinary Science and Veterinary Medicine | 1 | 33% |
| Agricultural and Biological Sciences | 1 | 33% |
| Unknown | 1 | 33% |